Trial of Telmisartan 80mg/HCTZ 12.5mg and Telmisartan 40mg/HCTZ 12.5mg in Patients With Hypertension

Condition(s) targeted: Hypertension

Intervention: Telmisartan 40 mg/HCTZ 12.5 mg (Drug); Telmisartan 40 mg (Drug); Telmisartan 80 mg/HCTZ 12.5 mg (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Boehringer Ingelheim Pharmaceuticals

Official(s) and/or principal investigator(s):
Boehringer Ingelheim Study Coordinator, Study Chair, Affiliation: Nippon Boehringer Ingelheim Co., Ltd.

The objective of this trial is to assess the safety and efficacy of 52 weeks of open-label treatment with the fixed dose combination of telmisartan 80 mg plus HCTZ 12. 5 mg and telmisartan 40 mg plus H CTZ 12. 5 mg in patients with essential hypertension.

Official title: An Open-Label, Long-Term (52-Week), Safety Trial of the Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg and Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg in Patients With Essential Hypertension - Efficacy and Safety Evaluation

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study

Primary outcome: The primary endpoint is safety of 52 weeks of open-label treatment.

Secondary outcome: The secondary endpoint is efficacy after 12 weeks of combination treatment.

Detailed description: This is a multi-centre study with three centres participating with a target of 30 to 90 patients ent ering the maintenance period and 20-60 patients completing long-term treatment per centre. The recr uitment period will be about three months from the start of the study.

Study Hypothesis:

The primary objective of this study is to demonstrate the long-term safety of a fixed dose combination of telmisartan/HCTZ fixed-dose combination treatment. This study has no control group; therefore, no hypothesis testing will be performed.

Comparison(s):

This study has no control group.

Minimum age: 20 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

1. Essential hypertensive patients who meet the following criteria:

- In case of using any antihypertensives, mean seated DBP* must be over 90 and

under 114 mmHg at Visit 1

- In case of not using any antihypertensives, mean seated DBP* must be over 95 and

under 114 mmHg at Visit 1

- Mean seated DBP* must be over 90 at Visit 2 *: The mean DBP values will be

calculated as the average of three seated measurements taken at two-minute intervals.

2. Age over 20and under 80years at Visit 1 (Male or Female)

3. Outpatient

4. Patients who are able to stop current anti-hypertensive therapy at Visit 1 if taking any anti-hypertensive medications

5. Patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as Good Clinical Practice (GCP) and the Pharmaceutical Affairs Law.

1. Patients taking four or more anti-hypertensive medications at Visit 1 2. Patients with known or suspected secondary hypertension (renovascular hypertension, primary aldosteronism, pheochromocytoma, etc.) 3. Patients whose mean seated DBP > 114 mmHg and/or mean seated SBP > 200 mmHg at Visit 1, Visit 2 or Visit 3 4. Patients with sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias (AV-block II-III, atrial fibrillation etc.) 5. Patients with NYHA functional class heart failure III-IV 6. Patients with a history of myocardial infarction or cardiac surgery within last 6 3 months before signing the informed consent form 7. Patients with a history of coronary artery bypass surgery or percutaneous transluminal coronary angioplasty (PTCA) within last 3 months before signing the informed consent form 8. Patients with a history of unstable angina within last 3 months before signing the informed consent form 9. Patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve 10. Patients with a history of stroke or transient ischemic attack within last 6 months before signing the informed consent form 11. Patients with a history of sudden exacerbation of renal function with AT1 receptor antagonists or ACE inhibitors; post-renal transplant 12. Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with AT1 receptor antagonists or ACE inhibitors 13. Patients with known hypersensitivity to any component of the formulation, or a known hypersensitivity to sulfonamides or sulfonamide-derived drugs (e. g. thiazides) 14. Known, suspected or history of gout

Boehringer Ingelheim Investigational Site, Sapporo-shi, Hokkaido 060-0003, Japan

Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo 160-0023, Japan

Boehringer Ingelheim Investigational Site, Hiroshima-shi, Hiroshima 733-0011, Japan

Ending date: August 2007
Last updated: December 18, 2007